Category: 142327-44-4

On January 10, 2008, Cook, Anthony; McInally, Tom; Thom, Stephen; Wada, Hiroki published a patent.Name: Methyl 2-(3-formylphenyl)acetate The title of the patent was Preparation of 8-oxoadenine derivatives as modulators of TLR7. And the patent contained the following:

8-Oxoadenine derivatives of formula I [A = aryl, heteroaryl; R1 = H, OH, alkoxy, aryl, cycloalkyl, etc.; Y1-Y3 = bond, alkylene; X1 = bond, O, S, SO2, (substituted) NH; Z1 = alkylene, cycloalkylene; R2 = H, alkyl, cycloalkyl, etc.; R3 = alkyl, hydroxyalkyl, alkoxy, (substituted) amino, etc.; R4 = (substituted) CO2H, SO2NH2, acyl, etc.; n = 0-2] are prepared The 8-oxoadenine derivatives act as modulators of Toll-like Receptor (TLR) 7 and thus may be used in the treatment of asthma, hepatitis, allergic diseases, viral and bacterial infection as well as cancer. Thus, II was prepared, and had pMEC > 7.7 in human TLR7 assay. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Name: Methyl 2-(3-formylphenyl)acetate

The Article related to oxoadenine preparation tlr7 modulator, Biomolecules and Their Synthetic Analogs: Others, Including Purines, Pyrimidine Nucleic Acid Bases, Flavins, Lignans and other aspects.Name: Methyl 2-(3-formylphenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 22, 2007, McInally, Thomas; Thom, Stephen; Wada, Hiroki published a patent.Product Details of 142327-44-4 The title of the patent was Purine derivatives having immunomodulating properties. And the patent contained the following:

Purine derivatives, such as I [R = amino group, such as NMe2 or NHMe, or a N-bound nitrogen containing heterocycle, such as 1-pyrrolidinyl or 4-methyl-1-piperazinyl; X = alkylene linking group, such as (CH2)m, m = 3, 4; X1 = alkylene linking group, such as (CH2)n, n = 2, 3], were prepared for use in immunomodulating pharmaceutical compositions which are useful in the treatment of diseases or conditions in which modulation of TLR7 activity is beneficial. These diseases or conditions may include allergic or viral diseases, cancers, asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis. Thus, purine derivative I [R = NMe2, X = X1 = (CH2)3] was prepared in 10 steps starting from 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine, BuONa, Br(CH2)3Br, H2N(CH2)3OH, and BrCH2-3-C6H4CH2CO2Me. The prepared purine derivatives were tested for interferon inducing activity in rat spleen cells and for activation of recombinant human TLR7. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Product Details of 142327-44-4

The Article related to purine derivative preparation immunomodulator toll like receptor activity, Biomolecules and Their Synthetic Analogs: Others, Including Purines, Pyrimidine Nucleic Acid Bases, Flavins, Lignans and other aspects.Product Details of 142327-44-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 29, 2007, Abbott, Philip; Bonnert, Roger Victor; Brough, Stephen; Chohan, Kamaldeep; McInally, Thomas; Thom, Stephen; Isobe, Yoshiaki; Nakamura, Kei; Tojo, Shingo published a patent.Electric Literature of 142327-44-4 The title of the patent was Purine derivatives for the treatment of viral or allergic diseases and cancers. And the patent contained the following:

Purine derivatives, such as I [R = N-bound nitrogen containing heterocycle, such as 3-pyrrolidinyl, 3-azetidinyl or 1-methyl-4-piperidinyl; R3 = CH2CO2Me, R4 = H, or R3 = H, R4 = CH2CO2Me; X = alkylene linking group, such as (CH)n, n = 3, 4], were prepared for use in immunomodulating pharmaceutical compositions which are useful in the treatment of diseases or conditions in which modulation of TLR7 activity is beneficial. These diseases or conditions may include allergic or viral diseases, cancers, asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis. Thus, purine derivative I [R = 4-piperidinyl, R3 = CH2CO2Me, R4 = H; X = (CH2)3] was prepared in 8 steps starting from 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine, BuONa, Br(CH2)3NHCO2CMe3, 4-oxo-1-piperidinecarboxylic acid tert-Bu ester, and OHC-3-C6H4CH2CO2Me. The prepared purine derivatives were tested for interferon inducing activity in rat spleen cells and for activation of recombinant human TLR7. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Electric Literature of 142327-44-4

The Article related to purine derivative preparation immunomodulator toll like receptor activity, Biomolecules and Their Synthetic Analogs: Others, Including Purines, Pyrimidine Nucleic Acid Bases, Flavins, Lignans and other aspects.Electric Literature of 142327-44-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 20, 2007, Alcaraz, Lilian; Lister, Andrew; Pairaudeau, Garry published a patent.Product Details of 142327-44-4 The title of the patent was Preparation of aminohydroxyethylbenzothiazolones as β2 adrenoreceptor agonists. And the patent contained the following:

Title compounds ArCH(OH)CH2NHC(R1)(R2)TAXYWCR51R52NR3R4 [I Ar = 4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl; T = a bond, CR33R34, CR35R36CR37R38, CR39R40CR41R42CR43R44; W = a bond, CR45R46, CR47R48CR49R50; A = a bond, (un)substituted (hetero)aryl; X = a bond; Y = a bond, (un)substituted (hetero)aryl; but A and Y not both a bond; R3, R4 = independently H, (un)substituted alkyl, heterocyclyl, cycloalkyl; or R3NR4 = (un)substituted 4-12 membered monocyclyl or bicyclyl; R33-R50 = independently H, alkyl; and their pharmaceutically acceptable salts], (e.g., II•2TFA), were prepared as β2 adrenoreceptor agonists. Thus, a multi-step synthesis from Et 2-(3-methylphenyl)acetate was given for benzothiazolone salt II•2TFA. Selected I were tested for adrenergic β2 mediated cAMP production Certain benzothiazolones I were at least 10-fold more potent at the β2 receptor compared to the α1, β1, or dopamine (D2) as demonstrated by selectivity assays. I, and their pharmaceutical compositions, are useful for the treatment of diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Product Details of 142327-44-4

The Article related to aminohydroxyethylbenzothiazolone preparation beta2 adrenoreceptor agonist respiratory disease, benzothiazolone hydroxy aminohydroxyethyl preparation beta2 adrenoreceptor agonist and other aspects.Product Details of 142327-44-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 11, 2018, Barth, Martine; Contal, Sylvie published a patent.Recommanded Product: 142327-44-4 The title of the patent was Preparation of dioxobenzothiazolyl hydrazides as inhibitors of YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma. And the patent contained the following:

The invention relates to preparation of dioxobenzothiazolyl hydrazides of formula I as inhibitors of the YAP/TAZ-TEAD protein interaction. Compounds I wherein R1 is (un)substituted aryl; R2 is (un)substituted alkyl; R3-R6 each independently is halo, alkoxyl, alkylthio, etc.; R7 is H or alkyl, are claimed. Compounds I were evaluated for their biol. activities (data given). Compounds I are useful as inhibitors of the YAP/TAZ-TEAD interactions and can be used in treatment of cancers, such as malignant mesothelioma. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Recommanded Product: 142327-44-4

The Article related to dioxobenzothiazolyl hydrazide preparation yap taz tead interaction inhibitor antitumor, malignant mesothelioma treatment dioxobenzothiazolyl hydrazide preparation protein interaction inhibitor and other aspects.Recommanded Product: 142327-44-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 20, 2013, Heckel, Armin; Blum, Andreas; Hamprecht, Dieter; Kley, Joerg published a patent.Recommanded Product: Methyl 2-(3-formylphenyl)acetate The title of the patent was Preparation of heterocyclic compounds for treating lung and airways diseases. And the patent contained the following:

The present invention relates to compounds I [R1, R2 = H or alkyl; R3, R4 = H or Me; or R3 and R4 together form ethylene bridge; R5 = H, alkyl, alkylOC(O), etc.; R6 = H, halo, CN, etc.; R7 = H, halo, CN, etc.; R8 = H, halo, CN, etc.; R9 = H or Me; m, n = 0-2 (with the proviso that m+n<4); X = halo; L1 = a bond, CH2, CH2CH2, CH2O, etc.] and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacol. properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways. Over 100 compounds I were prepared For example, reacting 3,5-diamino-6-chloro-N-[(methylsulfanyl)methanimidoyl]pyrazine-2-carboxamide with Me (4-aminopiperidin-1-yl)methyl-3-methoxybenzoate afforded 44% II. Exemplified compounds I were tested for their epithelial sodium channel inhibitory activity (data given). Pharmaceutical compositions comprising compound I, alone or in combination with other therapeutic agents, were disclosed. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Recommanded Product: Methyl 2-(3-formylphenyl)acetate

The Article related to heterocyclic pyrazinecarboxamide preparation epithelial sodium channel enac inhibitor allergy, lung airway respiratory disease treatment antiasthmatic heterocyclic pyrazinecarboxamide preparation and other aspects.Recommanded Product: Methyl 2-(3-formylphenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Hasanin, Mohamed S.; Abdelraof, Mohamed; Fikry, Mohamed; Shaker, Yasser M.; Sweed, Ayman M. K.; Senge, Mathias O. published an article in 2021, the title of the article was Development of antimicrobial laser-induced photodynamic therapy based on ethylcellulose/chitosan nanocomposite with 5,10,15,20-tetrakis(m-hydroxyphenyl)porphyrin.Electric Literature of 142327-44-4 And the article contains the following content:

The development of new antimicrobial strategies that act more efficiently than traditional antibiotics is becoming a necessity to combat multidrug-resistant pathogens. Here we report the efficacy of laser-light-irradiated 5,10,15,20-tetrakis(m-hydroxyphenyl)porphyrin (mTHPP) loaded onto an ethylcellulose (EC)/chitosan (Chs) nanocomposite in eradicating multi-drug resistant Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans. Surface loading of the ethylcelllose/chitosan composite with mTHPP was carried out and the resulting nanocomposite was fully characterized. The results indicate that the prepared nanocomposite incorporates mTHPP inside, and that the composite acquired an overall pos. charge. The incorporation of mTHPP into the nanocomposite enhanced the photo- and thermal stability. Different laser wavelengths (458; 476; 488; 515; 635 nm), powers (5-70 mW), and exposure times (15-45 min) were investigated in the antimicrobial photodynamic therapy (aPDT) experiments, with the best inhibition observed using 635 nm with the mTHPP EC/Chs nanocomposite for C. albicans (59 ± 0.21%), P. aeruginosa (71.7 ± 1.72%), and S. aureus (74.2 ± 1.26%) with illumination of only 15 min. Utilization of higher doses (70 mW) for longer periods achieved more eradication of microbial growth. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Electric Literature of 142327-44-4

The Article related to ethylcellulose chitosan mthpp nanocomposite antimicrobial laser photodynamic therapy, antimicrobial, chitosan, ethylcellulose, laser light, mthpp, multidrug resistance, nanocomposite, photodynamic therapy and other aspects.Electric Literature of 142327-44-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On July 23, 2009, Kurimoto, Ayumu; Katoda, Wataru; Hashimoto, Kazuki; Takahashi, Kazuhiko published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of adenine compound. And the patent contained the following:

The title compounds I [A1 = (CH2)m; A2 = (CH2)n; R1 = alkyl; R2, R3 = H, alkyl; or NR2R3 = pyrrolidine, morpholine, thiomorpholine, etc.; R4 = alkyl; m, n = integer from 2 to 5] are prepared by debenzylation of II [p = 1 or 2; R = H, halo, alkyl, etc.; A1, A2, R1 – R3, m, n = as defined above], followed by reaction with alkyl (3-formylphenyl)acetate in the presence of a boron-containing reducing agent. I are useful as pharmaceuticals (no data). Thus, debenzylation of 6-(benzylamino)-2-butoxy-9-(3-[(3-morpholin-4-ylpropyl)amino]propyl)-7,9-dihydro-8H-purin-8-one, followed by reaction with Me (3-formylphenyl)acetate in the presence of sodium triacetoxyborohydride, gave Me (3-([[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl)phenyl)acetate. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Category: esters-buliding-blocks

The Article related to benzylaminobutoxymorpholinylpropylaminopropyldihydropurinone debenzylation, aminobutoxyoxodihydropurinylpropylmorpholinylpropylaminomethylphenylacetate preparation, aminobutoxymorpholinylpropylaminopropyldihydropurinone reaction formylphenylacetate sodium triacetoxyborohydride and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 29, 2007, Hashimoto, Kazuki; Nakamura, Tomoaki; Nakamura, Kei; Kurimoto, Ayumu; Isobe, Yoshiaki published a patent.Quality Control of Methyl 2-(3-formylphenyl)acetate The title of the patent was Preparation of novel adenine compounds having immunomodulating activity. And the patent contained the following:

Novel N-benzyl- and 9-(3-pyridyl)-7,8-dihydro-8-oxoadenine derivatives represented by the formula (I) [A1, A2 = each (un)substituted aromatic carbocycle or aromatic heterocycle; L4 = independently a single bond or linear or branched alkylene; X = O, S, SO, SO2, NH, or alkyl-N; L1, L2, L3 = single bond, alkylene, alkenylene, or alkynylene wherein any methylene group is optionally replaced with O, S, SO, SO2, CO, or each N-(un)substituted alkyl-(un)substituted NHCO, CONH, NHSO2, SO2NH, NHCO2, O2CNH, NHCONH, NHC(:NH)NH, or C(:NH)NH; R1 = halo, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl; R2 = H or (un)substituted alkyl; R3 = each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, saturated heterocyclyl, aryl, or heteroaryl; any methylene, methine, or imino group in L2 or L3 is bonded to R3 on the N atom adjacent to L2 an dL3 to form 4- to 7-membered N-containing heterocyclic ring] or pharmaceutically acceptable salts thereof were prepared The compounds have activity of activating Toll-like receptor (TLR7) and useful as immunomodulators for treating and/or preventing allergies, viral diseases, and cancers, in particular asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, allergic conjunctivitis, atopic dermatitis, hepatitis B, hepatitis C, human immunodeficiency virus (HIV), human papillomavirus (HPV), bacterial infection, or dermatitis (no data). Thus, mesylation of 2-butoxy-9-[6-(4-hydroxybutoxy)pyridin-3-yl]-8-methoxyadenine by methanesulfonyl chloride in the presence of 4-dimethylaminopyridine and Et3N in THF at room temperature for 30 min followed by condensation with 2-(aminomethyl)phenylacetic acid Me ester in the presence of NaI and K2CO3 in DMF at 60° for 48 h gave 2-butoxy-8-methoxy-9-[6-[4-(3-methoxycarbonylmethylbenzyl)aminobutoxy]pyridin-3-ylmethyl]adenine which was stirred with a mixture of concentrated H2SO4 and MeOH and neutralized with 28% aqueous NH3 solution to give 2-butoxy-7,8-dihydro-9-(6-[4-(3-methoxycarbonylmethylbenzyl)aminobutoxy]pyridin-3-ylmethyl)-8-oxoadenine. II activated human TLR-7 in HEK293 cells with EC50 of 9.1 nM in a human TLR-7 reporter assay. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Quality Control of Methyl 2-(3-formylphenyl)acetate

The Article related to dihydrooxoadenine preparation immunomodulator, pyridinylmethyldihydrooxoadenine benzyldihydrooxoadenine preparation immunomodulator, toll like receptor tlr7 activator dihydrooxoadenine preparation, allergy viral disease cancer treatment prevention dihydrooxoadenine preparation and other aspects.Quality Control of Methyl 2-(3-formylphenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 28, 2009, Bennett, Nicholas J.; Mcinally, Thomas; Mochel, Tobias; Thom, Stephen; Tiden, Anna-Karin published a patent.Recommanded Product: 142327-44-4 The title of the patent was Preparation of pyrimidine derivatives for the treatment of various diseases. And the patent contained the following:

The title compounds I [R1 = alkyl, alkoxy, alkylthio;; R2 = II or III; R3 = H or alkyl; R4 = cycloalkyl, alkyl, alkenyl, alkynyl, etc.; X1 = O, S, NH or CH2; X2, X4 = a bond, O, S; R5, R51 = H or alkyl; R6 = (un)substituted alkyl or saturated heterocyclyl; j = 1-2; R7 = H, halo, OH, etc.; Z1 = alkylene or cycloalkylene; X3 = NR12, N(COR12), CONR12, etc.; Y1 = 0-2; Y1 = a bond, alkylene; A = monocyclic or bicyclic aryl or monocyclic or bicyclic heteroaryl containing 1-3 heteroatoms; R8 = (un)substituted alkyl; n = 0-2; R9 = halo, CN, OH, etc.; R12 = H, 3-8 membered (un)saturated heterocyclyl, alkyl, etc.], useful in the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis, were prepared E,g. a multi-step synthesis of IV, starting from 2-amino-4-chloro-6-methylpyrimidine and pentylamine, was given. Exemplified compounds I were tested in human TLR7 assay. For example, IV showed pEC50 of 6.3. Pharmaceutical compositions comprising the compound I, alone or in combination with other therapeutic agent, were disclosed. The experimental process involved the reaction of Methyl 2-(3-formylphenyl)acetate(cas: 142327-44-4).Recommanded Product: 142327-44-4

The Article related to pyrimidine pyrimidinediamine preparation antiasthmatic antitumor antibacterial antiaids, copd allergic rhinitis conjunctivitis atopic dermatitis treatment pyrimidinediamine preparation, hepatitis b c hiv hpv dermatosis treatment pyrimidinediamine preparation, toll like receptor tlr 7 modulator pyrimidine pyrimidinediamine preparation and other aspects.Recommanded Product: 142327-44-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics